To model and investigate different facets of leukemia pathogenesis, a widely accepted approach is to use immortalized leukemia cell lines. Although these provide powerful tools to our knowledge, few studies have addressed the question whether hematopoietic cell lines represent accurate and reliable model systems. To improve the molecular characterization of these model systems, we analyzed 17 myeloid leukemia cell lines using DNA microarray technology. By array-based comparative genomic hybridization, we identified recurrent genomic DNA gains and losses, as well as high-level amplifications. Parallel analysis of gene expression helped delineate potential candidate genes, and unsupervised analysis of gene expression data revealed cell lines to cluster in part based on underlying cytogenetic abnormalities. Comparison with clinical leukemia specimens showed that key signatures were retained, as myeloid cell lines with characteristic cytogenetic aberrations co-clustered with leukemia samples carrying the respective abnormality. Signatures were also quite robust, as expression data from cell lines correlated highly with published data. Thus, our analyses demonstrate myeloid cell lines to exhibit conserved and stable signatures reflecting the underlying primary cytogenetic aberrations. Our refined molecular characterization of myeloid cell lines supports the utility of cell lines as faithful and powerful model systems and provides additional insights into the molecular mechanisms of leukemogenesis.
Introduction
Myeloid leukemias are clonal disorders that are characterized by cytogenetic and molecular-genetic aberrations resulting in altered gene expression. However, the current World Health Organization classification of the myeloid neoplasms 1,2 does not fully reflect the molecular heterogeneity of myeloid leukemia. Recently, advances have been made in our understanding of the genetic basis of these malignancies, which have provided important insights into the pathogenesis of myeloid disorders. 3 Nevertheless, despite recent progress, there is still much to learn about the underlying mechanisms of leukemogenesis.
To model and investigate the different aspects of leukemia pathogenesis, a widely accepted approach is to use immortalized leukemia cell lines. 4 Although cell lines provide powerful tools for the investigation of gene function, the dissection of signal transduction pathways, and the analysis of drug effects, to our knowledge, few studies have addressed the question whether hematopoietic cell lines represent relevant and reliable model systems. 5, 6 Today, DNA microarray-based technologies have provided the power of genome-wide analysis of both genomic DNA copy number alterations (CNAs) and global gene expression changes. Array-based comparative genomic hybridization (array CGH) allows the screening of genomic imbalances with a 20-to 100-fold higher spatial resolution than conventional CGH. [7] [8] [9] The potential of this technology for the detection of genomic amplifications has recently been demonstrated in a study on acute myeloid leukemia (AML) cases with complex karyotypes (Rucker et al. ASH Annual Meeting Abstracts, Blood 2005; 106: 2357, abstract). In addition, parallel analysis of gene expression using microarray technology has been shown to provide useful information regarding the delineation of candidate genes in genomic regions characterized by CNAs. 10, 11 In order to improve the molecular characterization of commonly used myeloid cell line model systems, we analyzed 17 myeloid leukemia cell lines using DNA microarray technology. To determine the secondary aberrations acquired in addition to their characteristic primary cytogenetic aberrations, we first investigated all cell lines by array CGH using a BAC/PAC platform with an average resolution of B1.5 Mb across the entire genome. In parallel, we profiled gene expression using a whole genome cDNA microarray platform to further delineate potential candidate genes in the affected regions. In addition, we compared expression profiles with previously published AML patient data 12 and cell line data 5 to investigate whether cell lines exhibit conserved signatures correlating with the primary balanced cytogenetic aberrations, and whether they exhibit stable signatures. Thereby, we provide a refined molecular characterization of myeloid cell lines enabling an improved interpretation of cell line-derived data and supporting the utility of cell lines as powerful model systems. Furthermore, our findings provide additional insights into the molecular mechanisms of leukemogenesis.
Materials and methods

Cell lines
The myeloid cell lines CMK, HEL, HL-60, K-562, KASUMI-1, KG-1, LAMA-84, M-07e, MONO-MAC-1, MV4-11, NB-4, OCI-AML2, OCI-AML5, SIG-M5, THP-1 and UT-7 were obtained from the DSMZ in Braunschweig, Germany (http:// www.dsmz.de). The cell line ME-1 was kindly provided by Dr Ikuya Sakai, Ehime University, Japan. Cell lines were cultured under standard conditions in RPMI 1640 containing 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 U/ml streptomycin. For subsequent DNA and RNA isolation, 1 Â 10 cells of the respective cell lines were washed twice in phosphate-buffered saline, and stored as cell pellets at À801C.
Array comparative genomic hybridization
Array CGH experiments were performed as described previously using a 2.8k BAC/PAC microarray platform (Rucker et al. ASH Annual Meeting Abstracts, Blood 2005; 106: 2357, abstract). In brief, genomic DNA of the tumor specimens was isolated using standard protocols. Pooled PB DNA from five female or five male healthy volunteers was used as common reference in each experiment. In total, 300 ng cell line DNA and reference DNA were differentially labeled with Cy5-and Cy3-conjugated dCTP by random primed labeling, respectively. To have an internal control, cell lines derived from male tumors were cohybridized with the differentially labeled female reference DNA pool and vice versa. For the hybridization, we followed our previously published protocol. 13 Microarrays were imaged using a dual-laser scanner and the GenePixt Pro 6.0 imaging software (GenePixt 4000B, Axon Instruments, Union City, CA, USA). Raw data were analyzed as described previously. 13 Fluorescence ratios were normalized using the median of the fluorescence ratios computed as log 2 values from the 1503 DNA control fragments spanning the whole genome. The cutoff level was determined for each individual experiment by using an individual set of balanced clones that was used to calculate the mean and standard deviation. The cutoff level was then defined as mean plus/minus three times the standard deviation. The entire normalized array CGH data set is provided as Supplementary Table 1 .
Frequently affected regions, recently detected as copy number polymorphisms (5q11, 7q22, 7q35, 14q32 and 15q11), were excluded from data analysis. 14, 15 Gene expression profiling Gene expression profiling was performed essentially as described using the previously described cDNA microarray platform. 12 We normalized fluorescence ratios by mean-centering genes for each array, and then by mean centering each gene across all arrays. For subsequent analyses, only well-measured genes were included whose expression varied as determined by signal intensity over background greater than two-fold in either test or reference channel in at least 75% of samples, and fourfold ratio variation from the mean in at least two samples; 2725 genes met these criteria. The complete gene expression microarray data set is available at the Stanford Microarray Database (http://smd.stanford.edu) 16 and the filtered data set is provided as Supplementary Table 2 .
For hierarchical clustering, we applied average linkage hierarchical clustering and visualized results using TreeView. 17 For two-class supervised analyses, we used the Significance Analysis of Microarrays (SAM) method, 18 which utilizes a modified t-test statistic, with sample-label permutations to evaluate statistical significance.
Parallel analysis of gene expression and array CGH data was performed as described previously. 10, 11 Map positions for arrayed cDNA clones were assigned using the NCBI May 2005 genome assembly, accessed through the UCSC genome browser. In this way, approximately 35 000 arrayed clones representing 18 000 unique genes could be assigned map positions.
Comparison with primary acute myeloid leukemia samples
To investigate whether signatures underlying characteristic cytogenetic aberrations remain conserved in myeloid cell lines, we compared our results with a previously published AML gene expression data set. 12 For this analysis, we combined the raw data of the 116 AML cases and 17 cell lines and re-filtered them. In accordance with our previous analysis 12 and as reported in the previous section, fluorescence ratios of all samples were normalized by mean-centering genes for each array, and then by mean centering each gene across all arrays within each of the array print runs, to minimize potential print run-specific bias. We included only well-measured genes whose expression varied as determined by (1) signal intensity over background greater than two-fold in either test or reference channel in at least 75% of samples and (2) four-fold ratio variation from the mean in at least two samples; 9778 genes met these criteria. To eliminate the 'cell line'-specific signature (proliferation, etc.), we mean centered each gene again within the AML cases and within the cell line samples. 19 From the resulting data, we extracted the genes, which by multiclass SAM analysis have been previously identified to best characterize cytogenetic subgroups in AML. 12 The overlapping 717 genes (the original SAM-derived multiclass signature contained 728 genes) were then used for hierarchical clustering.
Comparison with published cell line data
To compare our findings with published cDNA microarrayderived gene expression data for the common subset of 12 cell lines 5 based on the provided gene symbols, we first determined the overlapping genes between the two filtered data sets. Then, in each data set, multiple clones representing a single gene were averaged. This resulted in an overlapping set of 1112 genes. To eliminate a potential 'experimenter-based' signature, we mean centered each gene within each of the two cell line data sets before hierarchical cluster analysis.
Results
Characterization of myeloid cell lines by arraycomparative genomic hybridization
In order to better characterize the 17 publicly available and widely used myeloid cell lines, we performed array CGH to profile CNAs in these cell lines at high resolution. Array CGH results provided considerably refined information showing that in addition to the primary cytogenetic aberrations the cell lines have acquired several CNAs, which are summarized in Table 1 and detailed array CGH data are provided as Supplementary  Table 1 .
The identified CNAs included several high-level amplifications mapping to 4q12 in KASUMI-1, to 8p11 in KG-1, to 8q24 in HL-60, to 9p24 and 9p21 in UT-7, to 9q34 in K-562 and to 8q24, 9p24, 12p12, 19p13 and 19q13 in NB-4. In agreement with the 'two hits' model of leukemogenesis, where one class of mutations impairs hematopoietic differentiation and a second one confers a proliferative and/or survival advantage, 20 the characterized amplicons contain many potential candidates responsible for the 'first' and/or 'second' hit.
For example, in KASUMI-1, we detected an approximately 14.9 Mb-sized amplification in 4q12 containing the KIT gene (Figure 1 ), which had been previously reported amplified, 21 and confirmed a known 8q24 amplification harboring MYC in HL-60. 22 However, many of our findings had not yet been reported, including amplifications involving the oncogene JAK2 in UT-7 and NB-4. Furthermore, in NB-4, we also found two distinct novel amplifications on chromosome 19 (amp(19)(p13) B6 Mb; amp(19)(q13) B7.5 Mb; Figure 2 ). Although gains on chromosome 19 or the long arm of chromosome 19 are frequently found by conventional CGH in acute megakaryocytic leukemia, 23 to our knowledge amplifications of 19p13 had not yet been described in AML. In addition, we detected a high-level amplification of approximately 12.6 Mb size in 12p12 containing KRAS, which also could confer a survival advantage for the blast cells in NB-4.
Furthermore, in nine cell lines, we detected genomic loss of 1p, and in 10 cell lines, we found 9p deletions with four cell lines showing both aberrations. The commonly deleted region (CDR) in 1p22 mapped to an approximately 10 Mb-sized region encompassing numerous genes. In 9p, the CDR was located in 9p21 harboring the INK4 family genes p15 and p16. Notably, in NB-4, count ratios suggested a biallelic deletion of the p15/p16 loci.
Parallel analysis of array-comparative genomic hybridization and gene expression reveals potential candidate genes in amplified regions
In parallel, we used a cDNA microarray platform to profile gene expression in the same set of myeloid cell lines, which was informative when integrated with the array CGH data. Consistent with our previous observations in AML with complex karyotypes (Rucker et al. ASH Annual Meeting Abstracts, Blood 2005; 106: 2357, abstract), we discovered a gene dosage effect within regions of DNA gain and loss. We detected significantly lower average gene expression levels across the genes located in deleted regions as compared to the average gene expression levels in unaltered regions. A similar effect was demonstrated in cases with chromosomal gains, which displayed significantly higher average gene expression levels across the respective regions.
By profiling gene expression in parallel, we were also able to identify within amplicons the relevant subset of candidate genes displaying comparably elevated expression. In KASUMI-1, the amplicon in 4q12 encompassed numerous genes with elevated expression, including KIT, FLJ13352, NRPS998 and SRP72. Interestingly, in KASUMI-1, a gain-of-function mutation of KIT (Asn822Lys) had been previously reported with the mutated allele exhibiting a five-fold higher expression level than the wild-type allele. 21 The 8q24 amplicons in HL-60 and NB-4 were associated with comparably higher expression levels of the known oncogene MYC, as well as elevated levels of FLJ32440 and C8FW (also known as TRIB1). Additional potential candidate genes located in other amplified regions which we had identified by array CGH are summarized in Table 1 . del(1)(p31p13),+8p THP-1 t(9;11)(p22;q23) gain(1)(p34),gain(6)(q12q25),del(9)(p21p13), À11p,gain(12)(q13) UT-7 amp(9)(p24p21),del(9)(p21) amp(9)(p24p21) JAK2
CGH, Comparative genomic hybridization.
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Gene expression profiling identifies distinct subgroups of myeloid cell lines
Analysis of the gene expression data on its own was also informative, where unsupervised hierarchical clustering of the 2725 most variably expressed genes revealed two distinct subgroups of myeloid cell lines (Figure 3a) . Interestingly, each of the two groups included cell lines with shared primary genetic aberrations within the group. The first group (cell lines colored in blue, Figure 3a ) comprised core binding factor (CBF) leukemia-derived cell lines (KASUMI-1 with a t(8;21), and ME-1 with an inv(16)) and cases with t(9;22) (K-562 and LAMA-84). In the second group (cell lines colored in red, Figure 3a) , cases with t(11q23) (THP-1, MV4-11 and MONO-MAC-1) clustered together based on similar gene expression patterns.
To further delineate the distinct gene expression patterns characterizing the hierarchical cluster-defined subgroups, we performed a two-class supervised analysis using SAM (Figure 3b ). Although group I (blue) was characterized by higher expression levels of, for example, TAL1 and BBC3, group II (red) displayed higher levels of EVI2A, EVI2B, CEBPA, ITGAL and NCAM1 (Figure 3b ).
Myeloid cell lines display retained signatures associated with primary cytogenetic aberrations
We were also interested to determine whether previously defined gene expression patterns associated with primary genetic aberrations like for example t(9;22), t(11q23) or aberrations affecting the CBF (inv(16) or t(8;21)) were retained in myeloid cell lines following numerous passages in vitro. Therefore, we performed supervised analyses for the abovementioned aberrations in our cell line data. Using SAM, we were able to identify gene expression patterns that were highly similar to known signatures associated with the respective cytogenetic leukemia subgroups (data not shown). For example, in accordance with our previous findings in AML blast samples, 12 the t(11q23) bearing cell lines were characterized by high levels of e.g. IGSF4, eIF2A, PBX3 and ADH1B.
Based on these results, we wanted to further define the extent to which the cytogenetic signatures retained in cultured myeloid cell lines were similar to those from actual clinical specimens. Therefore, we co-clustered our cell line data with data from 116 previously published AML patient samples, 12 using the genes that best characterized the different cytogenetic groups in AML (717 genes previously defined by multiclass SAM analysis). This cluster analysis demonstrated co-clustering of AML samples and cell lines carrying identical primary cytogenetic aberrations like for example t(8;21), inv(16) or t(15;17) (Figure 3c ).
Stability of myeloid cell line signatures
Cell lines represent commonly used model systems. Therefore, we were also interested to determine whether cell line signatures were stable in the sense that they would provide similar results when analyzed at different times in different laboratories. For that reason, we compared our findings with publicly available myeloid cell line data obtained using a different cDNA microarray platform, 5 for the subset of 12 cell lines in common between the two data sets. In an unsupervised hierarchical cluster analysis of the combined data sets (Figure 3d) , we identified high pair-wise correlations with coclustering for 11 of the 12 cell lines pairs, indicative of stable Molecular profiling of leukemia cell lines FG Rücker et al gene expression patterns. In HL-60, we observed a weaker correlation, but nevertheless the two HL-60 profiles were localized within the same cluster, and both cell lines showed high MYC expression levels (data not shown).
Discussion
We report here the comprehensive molecular profiling of 17 myeloid cell lines using DNA microarray technologies. The genomic characterization of these cell lines using array CGH has revealed numerous cytogenetic aberrations, many of which had not been described previously. Most importantly, we were able to disclose several regions of DNA amplification that in agreement with the 'two hits' model of leukemogenesis might represent one of the mutations impairing hematopoietic differentiation or conferring a proliferative and/or survival advantage. 20 Examples of such amplifications include the known oncogenes MYC in 8q24, JAK2 in 9p24 and ABL1 in 9q34. By discovering and characterizing such amplifications, these myeloid cell lines now represent improved model systems to investigate the potential pathogenic relevance of the respective aberrations, and our findings enable a more critical assessment of results derived from these cell lines. For example, in KASUMI-1, which is characterized by a t(8;21), amplification of the KIT locus in 4q12 might contribute to the malignant phenotype. Encoding for a receptor tyrosine kinase, KIT is commonly mutated in CBF leukemias, 24 and KIT mutations have been associated with inferior outcome. 25, 26 Thus, many of the findings observed in KASUMI-1 might in part be attributed to the concomitant KIT amplification.
Additional candidate genes involved in leukemogenesis, like e.g. C8FW (also known as TRIB1) in the 8q24 amplicon have been delineated by parallel analysis of gene expression. Interestingly, TRIB1 was also highly expressed in AML cases with complex karyotypes exhibiting high-level amplifications in 8q24 (Rucker et al. ASH Annual Meeting Abstracts, Blood 2005; 106: 2357, abstract). To our knowledge, ours is also the first study describing a genomic amplification in 19p13 in myeloid cell lines (Figure 2 ), although we have recently also identified two cases within our series of complex karyotypes (Rucker et al. ASH Annual Meeting Abstracts, Blood 2005; 106: 2357, abstract). In NB-4, the 19p13 amplification includes the costimulatory immune gene Interstitial Cell Adhesion Molecule 1 (ICAM1), which was also associated with higher expression levels. Interstitial Cell Adhesion Molecule 1 interacts with LFA1, the lymphocyte function antigen (CD11a), encoded by ITGAL, which was also highly expressed in the NB-4-containing myeloid cell line cluster (Figure 3b) . Interestingly, in the other cell lines in this cluster, which did not display amplification of ICAM1, expression of NCAM1 identified by microarray may provide the co-player for LFA1. These findings suggest a pathogenic role for the expression of co-stimulatory molecules in distinct subsets of AML possibly contributing to inferior outcome in AML patients. 27 The frequency in which we observed genomic losses in 1p and 9p (53 and 59%, respectively) was much higher than in AML cases with complex karyotypes (Rucker et al. ASH Annual Meeting Abstracts, Blood 2005; 106: 2357, abstract). This finding is in accordance with previous studies focusing on the role of p15/p16 in leukemogenesis that have shown a high incidence of p15/p16 inactivation by both deletion or hypermethylation of the promoter region in a large panel of leukemia and lymphoma cell lines. 28 Interestingly, it has also been shown that p15 and p16 aberrations were already present in the primary material. Thus, deletion of p15 or p16 does not occur during establishment of the cell lines or during prolonged cell culture. Being acquired in vivo p15/p16 deletion provides a growth advantage in vitro, thereby increasing the success rate for immortalization and explaining the high frequency of p15/16 deletion in cell lines. The high incidence of 1p deletions, which has not been reported yet, 29 most likely because of the relatively small size of the CDR in 1p22, might pinpoint to a mechanism similar to p15/p16 alterations that provides a survival advantage for the cell lines.
The gene expression pattern defining the above-mentioned myeloid leukemia cell line group was also characterized by higher levels of EVI2A and EVI2B, two genes implicated in retrovirus-induced murine myeloid tumors. 30 Interestingly, EVI2A and EVI2B are located within a large intron of the NF1 tumor suppressor gene, a region in which the breakpoints of translocations disrupting NF1 map. The other cluster-defined cell line group containing the CBF leukemia derived cell lines displayed lower CEBPA expression levels. This is an intriguing finding as the t(8;21) transfusion product acts as a repressor of CEBPA transcription. 31 Furthermore, these cell lines were characterized by elevated Stem cell leukemia/T-cell acute lymphoblastic leukemia 1 (SCL/TAL1) expression. Stem cell leukemia/T-cell acute lymphoblastic leukemia 1 plays a key role in controlling the development of primitive and definitive hematopoiesis, and the TAL1 expression level regulates immature human hematopoietic cell self-renewal. 32 Finally, correlation of our findings with gene expression patterns derived from AML patients 12 has clearly demonstrated that these myeloid cell lines retain conserved signatures associated with the primary balanced cytogenetic aberrations. These characteristic patterns might thus still be indispensable for cell growth in vitro. Similar observations have been made with lymphatic cell lines, 6 as well as with other leukemia and solid tumor derived cell lines. 33 In addition, comparison with available published cell line gene expression data 5 has demonstrated that the myeloid cell line signatures are also fairly stable. Astonishingly, all but one cell line co-clustered pair-wise. In HL-60, we observed a weaker correlation which nevertheless resulted in localization of the two HL-60 profiles within the same cluster. A possible explanation might be that this cell line is frequently found to be cross-contaminated. 34 In conclusion, our findings support the utility of myeloid leukemia cell lines as faithful model systems to study leukemogenesis, and provide confidence that reproducible results can be obtained even across different laboratories. In a variety of disciplines, human leukemia cell lines represent an extremely important resource for research. Thus, the refined molecular characterization of these cell lines provides not only additional insights into potential molecular mechanisms of leukemogenesis, but also provides an invaluable resource for all scientists working in this field.
